Last reviewed · How we verify
Insulin Lispro low mixture
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.
Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.
At a glance
| Generic name | Insulin Lispro low mixture |
|---|---|
| Also known as | LY275585[P] |
| Sponsor | Eli Lilly and Company |
| Drug class | Rapid-acting insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Insulin lispro is a recombinant human insulin analog with a rapid onset of action (within 15 minutes) and shorter duration compared to regular human insulin. It mimics the body's natural insulin response to meals by binding to insulin receptors, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. The low mixture formulation combines rapid-acting insulin lispro with intermediate-acting insulin lispro protamine suspension to provide both mealtime and basal glucose control.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Injection site reactions
- Weight gain
- Lipodystrophy
Key clinical trials
- Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies (PHASE4)
- Pre-Mix Insulin Lispro Treatment for Type 2 Diabetes Patients Who Consume a Light Breakfast (PHASE4)
- The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV) (PHASE4)
- Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin (PHASE4)
- Effects of Insulin in Perceived Mood Symptoms in Patients With Type 2 Diabetes (PHASE4)
- 24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine (PHASE4)
- A Study for Type 2 Diabetic Patients (PHASE4)
- Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin Lispro low mixture CI brief — competitive landscape report
- Insulin Lispro low mixture updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI